Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.

ABSTRACT:

SUBMITTER: Motzer R 

PROVIDER: S-EPMC10284118 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature